Intravenous immunoglobulins for the treatment of childhood autoimmune diseases
Over the last years it has become evident that intravenous immunoglobulins (IVIG) administered at high doses (HDIVIG) can have beneficial effects in autoimmune diseases. Most of the clinical information was obtained in patients with variants of immune thrombocytopenia (ITP). Further, most of the attempts to clarify the mode of action of HDIVIG have been made in ITP patients. Other inflammatory disorders pathogenetically unrelated to ITP also seem to respond to HDIVIG, and several authors have studied possible explanations for these effects. Table 1 summarizes biological effects supported by results from appropriate experiments. Further details can be found in comprehensive reviews (Ballow 1997, Kazatchkine and Kaveri 2001). This review focusses on mechanisms of HDIVIG in both ITP and other disorders.
KeywordsMajor Histocompatibility Complex Lupus Nephritis Intravenous Immunoglobulin Idiopathic Thrombocytopenic Purpura Kawasaki Syndrome
Unable to display preview. Download preview PDF.
- Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, Kazatchkine MD (1996) Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T-cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 97: 865–869PubMedCrossRefGoogle Scholar
- Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD (1996) Mechanism of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 104 Suppl 1: 3–9Google Scholar
- Prasad NKA, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV (1998) Therapeutic preparations of normal polyspecific IgG (IVIG) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIG involving the Fas apoptotic pathway. J Immunol 161: 3781–3790PubMedGoogle Scholar
- Shimozato T, Iwata M, Kawada H, Tamura N (1991) Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine B’rS’-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 72: 497–501PubMedGoogle Scholar
- Silvestris F, D’Amore 0Cafforio P, S a vino L, Dammacco F (1996) Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol 104 Suppl 1: 91–97Google Scholar
- Tsubakio T, Kurata Y, Katagiri S, Kanakura Y, Tamaki T, Kuyama J, Kanayama Y, Yonezawa T, Tarui S (1983) Alteration of T cell subsets and immunoglobulin synthesis in vitro during high-doseγ-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 53: 697–702PubMedGoogle Scholar
- Vassilev TL, Kazatchkine MD, van Huyen JPD, Mekrache M, Bonnin E, Mani JC, Lecroubier C, Korinth D, Baruch D, Schriever F, Kaveri SV (1999) Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIG). Blood 93: 3624–3631PubMedGoogle Scholar